LI
VYNT

Leap Investments’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Leap Investments’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,904
Closed -$116K – 623
2019
Q4 		$116K Buy
+3,904
New +$93.4K 0.05% 368

Other funds holding VYNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Leap Investments's VYNT Position: Q1 2020 in Review

Leap Investments sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2020, closing a stake of 3,904 shares — an estimated $116K sold.

Leap Investments first reported a position in VYNT in Q4 2019 and held it in 1 quarter. The position peaked at $116K in Q4 2019. 13 funds tracked by Wall St. Rank hold VYNT as of Q1 2020.

  • Leap Investments reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 3,904 Vyant Bio, Inc. Common Stock shares in Q1 2020, an estimated $116K.
  • Leap Investments first reported a position in Vyant Bio, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Leap Investments's Vyant Bio, Inc. Common Stock position peaked at $116K in Q4 2019.
  • 13 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.